EGFR and non-small cell lung carcinoma: Indeed, Asian patients with EGFRM+ NSCLC, who harbored this host BIM deletion polymorphism, exhibited significantly inferior responses to treatment with TKIs of all three generations and much shorter PFS than individuals lacking the polymorphism, suggesting that the BIM polymorphism is a negative predictive marker of response to EGFR-TKIs [218,219,220,221,222].